Resolution for sepsis?
Gilroy
Derek W
DW
Vallance
Patrick
P
D042683:Angiopoietin-1 / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000096:biosynthesis / Q000235:genetics; D003131:Combined Modality Therapy; D004790:Enzyme Induction / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D051379:Mice; D019001:Nitric Oxide Synthase / Q000096:biosynthesis / Q000235:genetics; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D042787:Receptor, TIE-2 / Q000502:physiology; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000628:therapy
D042683:Angiopoietin-1; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015815:Cell Adhesion Molecules; D007155:Immunologic Factors; C496319:NOS2 protein, human; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496317:Nos2 protein, mouse; C496315:Nos3 protein, mouse; D042787:Receptor, TIE-2